| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
59,420,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Generation Bio is a genetic medicines company providing durable, redosable treatments for potentially various of patients living with rare and prevalent diseases. Co.'s non-viral genetic medicine platform incorporates its DNA construct called closed-ended DNA; its cell-targeted lipid nanoparticle delivery system; and its capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, to produce ceDNA. Using Co.'s platform, it is developing genetic medicines to provide targeted delivery of genetic payloads that include large and multiple genes to a range of cell types across a range of diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
170,000 |
551,455 |
642,217 |
| Total Buy Value |
$0 |
$257,339 |
$778,895 |
$1,265,385 |
| Total People Bought |
0 |
2 |
4 |
4 |
| Total Buy Transactions |
0 |
4 |
7 |
12 |
| Total Shares Sold |
0 |
4,890 |
11,122 |
27,899 |
| Total Sell Value |
$0 |
$7,922 |
$39,768 |
$125,583 |
| Total People Sold |
0 |
2 |
2 |
2 |
| Total Sell Transactions |
0 |
2 |
4 |
10 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kerr Douglas |
CHIEF MEDICAL OFFICER |
• – – |
2021-01-11 |
4 |
OE |
$4.59 |
$51,716 |
D/D |
11,267 |
337,825 |
|
- |
|
| Nicholson Donald William |
|
– • – |
2021-01-11 |
4 |
B |
$24.50 |
$99,985 |
D/D |
4,081 |
103,157 |
0.01 |
- |
|
| Stanton Matthew |
CHIEF SCIENTIFIC OFFICER |
• – – |
2021-01-11 |
4 |
AS |
$27.18 |
$410,372 |
D/D |
(14,820) |
198,154 |
|
- |
|
| Stanton Matthew |
CHIEF SCIENTIFIC OFFICER |
• – – |
2021-01-11 |
4 |
OE |
$0.60 |
$8,892 |
D/D |
14,820 |
212,974 |
|
- |
|
| Angelino Mark D. |
Chief Operating Officer |
• – – |
2020-12-15 |
4 |
AS |
$34.87 |
$185,431 |
D/D |
(5,301) |
345,637 |
|
- |
|
| Angelino Mark D. |
Chief Operating Officer |
• – – |
2020-12-15 |
4 |
OE |
$4.59 |
$24,332 |
D/D |
5,301 |
350,938 |
|
- |
|
| Atlas Venture Opportunity Fund I, L.p. |
10% Owner |
– – • |
2020-12-15 |
4 |
AS |
$0.00 |
$0 |
I/I |
(1,151,882) |
11,478,876 |
|
- |
|
| Stanton Matthew |
Chief Scientific Officer |
• – – |
2020-12-10 |
4 |
AS |
$37.14 |
$396,499 |
D/D |
(10,540) |
198,154 |
|
- |
|
| Stanton Matthew |
Chief Scientific Officer |
• – – |
2020-12-10 |
4 |
OE |
$0.60 |
$6,324 |
D/D |
10,540 |
208,694 |
|
- |
|
| Angelino Mark D. |
Chief Operating Officer |
• – – |
2020-08-14 |
4 |
OE |
$0.60 |
$37,536 |
D/D |
62,560 |
345,637 |
|
- |
|
| Rhodes Jason P |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
I/I |
10,040,032 |
12,630,758 |
|
- |
|
| Wellington Biomedical Innovation Master Investors |
10% Owner |
– – • |
2020-06-16 |
4 |
B |
$19.00 |
$20,900,000 |
D/D |
1,100,000 |
2,112,546 |
2.45 |
- |
|
| Wellington Biomedical Innovation Master Investors |
10% Owner |
– – • |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,012,546 |
1,012,546 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
I/I |
10,040,032 |
12,630,758 |
|
- |
|
| Christensen Gustav |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
88,961 |
131,422 |
|
- |
|
| Mcdonough Geoff |
See Remarks |
• • • |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
113,231 |
1,479,080 |
|
- |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2020-06-16 |
4 |
B |
$19.00 |
$15,200,000 |
D/D |
800,000 |
2,814,191 |
2.45 |
- |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,014,191 |
2,014,191 |
|
- |
|
| Rowland Charles A Jr |
Director |
– • – |
2020-06-16 |
4 |
B |
$19.00 |
$570,000 |
D/D |
30,000 |
80,627 |
2.39 |
- |
|
| Rowland Charles A Jr |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
50,627 |
50,627 |
|
- |
|
| Nicholson Donald William |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
56,615 |
99,076 |
|
- |
|
| Quinn Anthony |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
30,376 |
72,837 |
|
- |
|
| Casdin Eli |
10% Owner |
– – • |
2020-06-16 |
4 |
B |
$19.00 |
$12,350,000 |
I/I |
650,000 |
1,611,215 |
1.5 |
- |
|
| Casdin Eli |
10% Owner |
– – • |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
I/I |
961,215 |
961,215 |
|
- |
|
| Stehman-Breen Catherine |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
5,062 |
47,523 |
|
- |
|
293 Records found
|
|
Page 11 of 12 |
|
|
